Gynecomastia: Understanding Enlarged Male Breast Tissue and Your Options

What is gynecomastia, and how is it different from chest fat?

True gynecomastia is the growth of actual glandular breast tissue in the male chest. It feels firm or rubbery and is typically centered directly behind the nipple-areolar complex. Pseudogynecomastia — sometimes called lipomastia — is an accumulation of fatty tissue in the chest without any increase in glandular tissue. The two can look nearly identical and often coexist.

Telling them apart matters because they have different causes and respond differently to treatment. Diet and exercise can meaningfully reduce chest fat, but they do not reduce true glandular tissue. A clinician can usually distinguish them on physical examination alone.

How common is gynecomastia?

Gynecomastia is far more common than most people realize. Population data suggest that up to 60 percent of boys develop clinically detectable breast tissue by age 14 [1, 2]. A large cross-sectional study of more than 530,000 boys confirmed that pubertal gynecomastia is the norm rather than the exception, with peak incidence around ages 13 to 14 2Ref 2Berger O, Hornik-Lurie T, Talisman R (2024).Pubertal gynecomastia incidence among 530,000 boys: a cross sectional population based study.Large population-based confirmation of pubertal gynecomastia prevalence and peak onset at ages 13-14; over 95% of pubertal cases physiological.

In older men, prevalence rises again: studies report rates of 36 to 57 percent in men over age 60 1Ref 1Swerdloff RS, Ng JCM (2023).Gynecomastia: Etiology, Diagnosis, and Treatment.Prevalence statistics (pubertal up to 60%, older men 36-57%), resolution rates (1-3 years, 20% residual at age 20), drug-induced ~20%, fibrosis timeline, malignancy risk in excised specimens 0.11%. Across all ages, medications or exogenous chemicals account for roughly 20 percent of cases 1Ref 1Swerdloff RS, Ng JCM (2023).Gynecomastia: Etiology, Diagnosis, and Treatment.Prevalence statistics (pubertal up to 60%, older men 36-57%), resolution rates (1-3 years, 20% residual at age 20), drug-induced ~20%, fibrosis timeline, malignancy risk in excised specimens 0.11%, and a systematic review of drug-induced gynecomastia confirmed that drugs represent one of the most identifiable causes 3Ref 3Trinchieri A, Perletti G, Magri V, Stamatiou K, Trinchieri M, Montanari E (2021).Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials.Systematic review confirming medication-induced gynecomastia; drug mechanisms including anti-androgenic effects, hyperprolactinemia, and exogenous estrogen exposure.

Why does gynecomastia develop?

The male body normally produces small amounts of estrogen alongside testosterone. When the ratio tips toward estrogen — either because estrogen rises, testosterone falls, or the sensitivity of breast tissue to each changes — glandular tissue can grow. This can happen for many reasons:

• Puberty: Transient hormonal surges during adolescence drive the majority of cases. Over 95 percent of pubertal gynecomastia is considered physiological 2Ref 2Berger O, Hornik-Lurie T, Talisman R (2024).Pubertal gynecomastia incidence among 530,000 boys: a cross sectional population based study.Large population-based confirmation of pubertal gynecomastia prevalence and peak onset at ages 13-14; over 95% of pubertal cases physiological.
• Aging: Testosterone naturally declines with age while body fat (which converts androgens to estrogen) often increases, shifting the hormonal balance.
• Obesity: Fat tissue is a site of aromatase activity, the enzyme that converts androgens into estrogens. Excess weight can both cause and amplify gynecomastia.
• Medications: A wide range of drugs are associated with gynecomastia, including anti-androgens, spironolactone, certain antihypertensives, antifungals, some antidepressants, anabolic steroids, and protease inhibitors used in HIV treatment [3, 4].
• Underlying medical conditions: Disorders affecting the testes, liver, thyroid, adrenal glands, or pituitary can all alter the hormonal environment that governs breast gland tissue.
• Idiopathic: In a substantial proportion of evaluated adults — around 45 percent in some studies — no clear cause is identified after a thorough workup 4Ref 4Kanakis GA, Nordkap L, Bang AK, et al. (2019).EAA clinical practice guidelines — gynecomastia evaluation and management.European Academy of Andrology structured evaluation and management guidelines; anabolic steroids (13.9%), hypogonadism (11.1%), drugs (7.8%) as identifiable adult causes; idiopathic in ~45% of cases.

In clinical practice, the most common identifiable causes in adult men are anabolic steroid use, hypogonadism, and prescription medications 4Ref 4Kanakis GA, Nordkap L, Bang AK, et al. (2019).EAA clinical practice guidelines — gynecomastia evaluation and management.European Academy of Andrology structured evaluation and management guidelines; anabolic steroids (13.9%), hypogonadism (11.1%), drugs (7.8%) as identifiable adult causes; idiopathic in ~45% of cases.

When does gynecomastia go away on its own?

Pubertal gynecomastia typically resolves within one to three years of onset as hormone levels stabilize 1Ref 1Swerdloff RS, Ng JCM (2023).Gynecomastia: Etiology, Diagnosis, and Treatment.Prevalence statistics (pubertal up to 60%, older men 36-57%), resolution rates (1-3 years, 20% residual at age 20), drug-induced ~20%, fibrosis timeline, malignancy risk in excised specimens 0.11%. By age 17, only about 10 percent of boys still have persistent breast tissue, and around 20 percent have residual gynecomastia at age 20 [1, 2].

Early gynecomastia — present for less than six months to a year — is more likely to respond to medical treatment and more likely to resolve spontaneously. Once the tissue has been present for more than one to two years, it tends to become fibrous and less reversible, making medical treatment alone less effective and surgical options more relevant [1, 5].

For medication-induced gynecomastia, stopping or switching the offending drug is always the first step; improvement is often apparent within weeks if the tissue is still in its early, active phase.

What are the treatment options for gynecomastia?

Treatment depends on the cause, how long the tissue has been present, and how much the condition is affecting your life.

Address the underlying cause first. If a medication is contributing, a clinician may consider adjusting or substituting it. If a medical condition is driving hormonal changes — hypogonadism, thyroid disease, liver disease — treating that condition sometimes reverses the breast changes.

Pharmacological options for early gynecomastia. Certain hormone-related medications — notably selective estrogen receptor modulators — have been used in early or pubertal gynecomastia. A systematic review of pharmacological treatments found that tamoxifen is appropriate in select patients, though the evidence base remains limited and high-quality trials are lacking 5Ref 5Berger O, Landau Z, Talisman R (2022).Gynecomastia: A systematic review of pharmacological treatments.Tamoxifen appropriate in select patients for pubertal gynecomastia; overall evidence base limited; surgery reserved for severe or persistent cases at end of puberty. These treatments must be prescribed and monitored by a clinician; they are not appropriate for all patients and are generally less effective once the tissue has become fibrous.

Surgery for persistent or established gynecomastia. For gynecomastia that has persisted beyond one to two years and has not responded to other approaches, surgical removal of the glandular tissue — with or without liposuction for the fatty component — is the most reliably effective option. Research consistently shows that combined subcutaneous mastectomy and liposuction produces high patient satisfaction and a low rate of complications 6Ref 6Lapid O, van Wingerden JJ, Perlemuter L (2015).Surgical Strategies in the Treatment of Gynecomastia Grade I-II: The Combination of Liposuction and Subcutaneous Mastectomy Provides Excellent Patient Outcome and Satisfaction.Combined liposuction and subcutaneous mastectomy is effective and safe with high patient satisfaction and low complication rates for gynecomastia. Surgery is typically offered toward the end of puberty in adolescents, and in adults whenever the condition is persistent and bothersome 5Ref 5Berger O, Landau Z, Talisman R (2022).Gynecomastia: A systematic review of pharmacological treatments.Tamoxifen appropriate in select patients for pubertal gynecomastia; overall evidence base limited; surgery reserved for severe or persistent cases at end of puberty.

Lifestyle changes. Weight loss and exercise can reduce the fatty component of the chest and improve overall appearance, but they do not reduce established glandular tissue. They are worth pursuing for general health and for pseudogynecomastia, but should not be expected to eliminate true gynecomastia on their own.

What will a clinician look for during evaluation?

A thorough evaluation typically starts with a history and physical examination. Clinicians distinguish glandular tissue from fat by palpation and assess for features that would raise concern for malignancy — such as a hard, irregular, or eccentric mass, nipple discharge, or skin changes 7Ref 7Mannix J, Duke H, Almajnooni A, Ongkeko M (2024).Imaging the Male Breast: Gynecomastia, Male Breast Cancer, and Beyond.Imaging distinction between gynecomastia (symmetric subareolar, often bilateral) and male breast cancer (irregular, eccentric, usually unilateral); overlap in retroareolar position; most solid male breast masses require tissue diagnosis.

If the history and exam do not point to an obvious cause, laboratory testing is often the next step:

• Hormone panel (total testosterone, estradiol, LH, FSH, prolactin) to assess for hypogonadism, testicular overproduction, or pituitary involvement.
• Thyroid function tests (TSH, free T4), since thyroid disorders can alter sex hormone binding.
• Liver and kidney function tests, because the liver metabolizes estrogen and chronic kidney disease is associated with hormonal changes that can cause gynecomastia.
• Testicular ultrasound when a testicular tumor is suspected as a hormone source.
• Breast imaging (ultrasound or mammography) when a unilateral or irregular mass needs further characterization 7Ref 7Mannix J, Duke H, Almajnooni A, Ongkeko M (2024).Imaging the Male Breast: Gynecomastia, Male Breast Cancer, and Beyond.Imaging distinction between gynecomastia (symmetric subareolar, often bilateral) and male breast cancer (irregular, eccentric, usually unilateral); overlap in retroareolar position; most solid male breast masses require tissue diagnosis.

The European Academy of Andrology clinical practice guidelines recommend a structured approach to gynecomastia that includes a focused history, physical examination, and targeted laboratory work before treatment decisions are made 4Ref 4Kanakis GA, Nordkap L, Bang AK, et al. (2019).EAA clinical practice guidelines — gynecomastia evaluation and management.European Academy of Andrology structured evaluation and management guidelines; anabolic steroids (13.9%), hypogonadism (11.1%), drugs (7.8%) as identifiable adult causes; idiopathic in ~45% of cases.

Does gynecomastia raise the risk of breast cancer?

Male breast cancer is rare, accounting for less than 1 percent of all breast cancers. Gynecomastia itself is not considered a premalignant condition: one analysis of surgically excised gynecomastia specimens found an overall prevalence of invasive carcinoma of only 0.11 percent 1Ref 1Swerdloff RS, Ng JCM (2023).Gynecomastia: Etiology, Diagnosis, and Treatment.Prevalence statistics (pubertal up to 60%, older men 36-57%), resolution rates (1-3 years, 20% residual at age 20), drug-induced ~20%, fibrosis timeline, malignancy risk in excised specimens 0.11%.

However, certain features should prompt evaluation to rule out malignancy: a hard, fixed, or irregular lump that is eccentric (off-center from the nipple); spontaneous or bloody nipple discharge; rapid asymmetric growth; skin dimpling or retraction; or enlarged lymph nodes under the arm. Imaging review confirms that male breast cancer tends to present as an irregular retroareolar mass, whereas benign gynecomastia arises symmetrically in a subareolar position and is often bilateral 7Ref 7Mannix J, Duke H, Almajnooni A, Ongkeko M (2024).Imaging the Male Breast: Gynecomastia, Male Breast Cancer, and Beyond.Imaging distinction between gynecomastia (symmetric subareolar, often bilateral) and male breast cancer (irregular, eccentric, usually unilateral); overlap in retroareolar position; most solid male breast masses require tissue diagnosis. When features are ambiguous, tissue sampling may be needed — most solid male breast masses warrant a definitive diagnosis.

The emotional weight of gynecomastia

Many people searching for this topic feel embarrassed, frustrated, or ashamed — those feelings are valid and extremely common. Research consistently documents that gynecomastia affects body image, self-esteem, and willingness to participate in activities that involve being seen (swimming, changing in public, exercise). A systematic review of studies examining psychological outcomes found that surgery significantly improves emotional discomfort, vitality, and psychosocial functioning in men who undergo treatment 8Ref 8Sollie M (2018).Management of gynecomastia — changes in psychological aspects after surgery — a systematic review.Surgical treatment of gynecomastia significantly improves vitality, emotional discomfort, limitations due to physical and pain-related aspects; systematic review of 6 studies. A cross-sectional study using the validated BODY-Q instrument similarly found improvements in quality of life and chest appearance satisfaction after adolescent gynecomastia surgery 9Ref 9Karpinski M, Tuen YJ, Courtemanche R, Arneja JS (2024).Quality of Life Measured Using the BODY-Q After Adolescent Gynecomastia Surgery: A Cross-Sectional Analysis.BODY-Q instrument demonstrates improved quality of life and chest appearance satisfaction after adolescent gynecomastia surgery.

If gynecomastia is weighing on your mental well-being, that is a completely legitimate reason to seek evaluation — not just a cosmetic concern. A good clinician will take that seriously.